Background {#Sec1}
==========

Diols are of great importance in the manufacture of plastics and polyurethanes, which have molded our society in many ways that make our life much easier \[[@CR1]\]. The biosynthesis of short-chain diols such as 1,3-propanediol and 1,4-butanediol has been well developed \[[@CR2]--[@CR5]\], while the long-chain α, ω-diols such as 1,14-tetradecanediol and 1,16-hexadecanediol can be made by the catalytic hydrogenation of long-chain dicarboxylate esters. The medium-chain diols with one subterminal hydroxyl group, for example, 1,7-decanediol, which confer more flexibility upon the synthesized materials, are promising monomers for the synthesis of polymers with better properties. But unfortunately, this type of diols has not yet been synthesized with either chemical or biological method. The strong market demand for new polymers drives us to develop a strategy for the synthesis of these diols.

To obtain the carbon backbones, we paid attention to the straight-chain fatty alcohols, whose biosynthesis has been well developed in recent years \[[@CR6]--[@CR8]\]. To finally get the desired diols, an additional hydroxyl group needs to be added to the subterminal carbon of the monohydric alcohols. But it is too difficult for the inorganic catalysts to catalyze the oxidation of a specific subterminal carbon of the monohydric alcohols, as each of the subterminal carbons almost has the same chemical contexts, and the inorganic catalysts usually exhibit poor selectivity. So the biocatalyst was considered as a priority. In seeking such a biocatalyst for the conversion of monohydric alcohols to corresponding diols, P450~BM3~ seems to be a promising enzyme, which naturally catalyzes the conversion of long-chain fatty acids to corresponding hydroxyfatty acids \[[@CR9], [@CR10]\]. P450~BM3~ is highly soluble in cytosolic environment, and has high catalytic rates and expression level in engineered *E. coli*, which is the most widely used host for the bioproduction of chemicals \[[@CR11], [@CR12]\]. These advantages make it an ideal biocatalyst for biotechnological application. And more importantly, its variants have shown to be able to utilize a wide range of other substrates. The P450~BM3~ variant 35-E11, whose 17 amino acid residues were substituted, was found to be capable of converting ethane to ethanol \[[@CR11]\], and a series of P450~BM3~ variants were reported the improved activities on non-natural substrates naphthalene, pentane, p-cymene and propylbenzene \[[@CR13]\]. These findings suggest that P450~BM3~ has stunning flexibility in substrate preference. In addition, protein engineering has been widely used as a strategy in the biological production of chemicals \[[@CR14], [@CR15]\]. Therefore, an improved regioselectivity for alcohol hydroxylation at ω-3 position can be expected by remodeled P450~BM3~ (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Schematic representation of the substrate specificities and regioselectivities of the native P450~BM3~ and the remodeled P450~BM3~. The native P450~BM3~ has a substrate preference for C12-C18 fatty acids and evenly oxidizes the ω-1, ω-2 and ω-3 carbons of the fatty acid substrates (**a**), while the remodeled P450~BM3~ exhibits a greatly improved regiospecificity of decanol hydroxylation, with 1,7-decanediol as the dominant product (**b**)

In this study, we are reporting a strategy for high-specificity synthesis of α, ω3-diols from renewable medium-chain fatty alcohols. To improve the regioselectivity for alcohol hydroxylation at ω-3 position, we generated a series of P450~BM3~ variants by laboratory evolution. We also identified several key amino acid residues that control the regioselectivity of alcohol hydroxylation, and discussed the reason why these residues play a key role in determining the regioselectivity by structural analysis.

Results and discussion {#Sec2}
======================

Substrate specificity and regioselectivity of P450~BM3~ {#Sec3}
-------------------------------------------------------

The P450~BM3~ was chosen as the starting enzyme for the conversion of alcohols to diols. So the engineered *E. coli* that overexpresses the native P450~BM3~ was constructed as the biocatalyst to test P450~BM3~'s ability of alcohol hydroxylation. The heptanol and decanol were firstly used as the substrates for testing the activity of P450~BM3~, as the medium chain diols are of more interests for the development of new polymers. P450~BM3~ exhibited high activities towards these substrates and produced almost an equivalent amount of α, ω1-, α, ω2- and α, ω3-diols, exhibiting the same regioselectivity as its native fatty acid substrates (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). But when using pentanol as the substrate, only a tiny amount of 1,4-pentanediol was obtained (Fig. [2](#Fig2){ref-type="fig"}), suggesting P450~BM3~ has a different regioselectivity for short-chain alcohols. No activity was observed when using propanol and butanol as the substrates.Fig. 2GC-MS analysis of diols in the cultures. When pentanol was used as substrate, both BM3 and BM3J produced 1,4-pentanediol as the only product (**a**, **d**). When heptanol and decanol were used as substrates, BM3J produced much more 1,4-heptanediol (**b**, **e**) and 1,7-decanediol (**c**, **f**) than BM3, respectivelyFig. 3Regiospecificities of the native P450~BM3~, P450~BM3J~ and corresponding 10 single mutants of P450~BM3J~. Decanol was used as the substrate, and 1,7-, 1,8- and 1,9-decanediols were analyzed by GC-MS. The ratio of 1,7-decanediol to total decanediols increased from 34.0 % in BM3 to \~50 % in R255S, suggesting the increased ratio of 1,7-decanediol to total decanediols in BM3J is mainly attributed to the substitution of Arg^255^ to Ser^255^. The other 9 amino acid substitutions may have a combined effect on the constriction of the substrate-binding channel and the change of the substrate orientation

As the typical substrates of P450~BM3~ are long-chain fatty acids \[[@CR16]\], it is not surprising that the short-chain fatty alcohols are poor substrates for P450~BM3~. Arg^47^ and Tyr^51^ were thought to interact with the carboxylate group of the fatty acid substrates \[[@CR17], [@CR18]\]. Our finding that P450~BM3~ is also capable of utilizing fatty alcohols demonstrates that the interaction between Arg^47^/Tyr^51^ and carboxylate group is not so strong, and Arg^47^/Tyr^51^ is not involved in determining the substrate specificity of P450~BM3~. If Arg^47^/Tyr^51^ is responsible for stabilizing the carboxylate group of the fatty acid substrates, the carboxylate group needs to be recognized by the two amino acid residues, and P450~BM3~ will not be able to oxidize those hydrocarbons without carboxylate group. Therefore, the size of the substrate-binding pocket plays an important role in determining the substrate specificity of P450~BM3~, given that the P450~BM3~ has no activity towards short-chain alcohols and alkanes \[[@CR19]\].

Substrate specificity and regioselectivity of P450~BM3J~ {#Sec4}
--------------------------------------------------------

For the high-specificity production of the α, ω3-diols, the native P450~BM3~ needs to be modified to change its regioselectivity for alcohol hydroxylation. The regioselectivity is connected with the substrate orientation, which could be changed when the substrate channel of P450~BM3~ is constrained. It was found that a P450~BM3~ variant (P450~BM3J~), which contains 10 amino acid substitutions (V78A, T175I, A184V, F205C, S226R, H236Q E252G, R255S, A290V, L353V) with respect to the native P450~BM3~, changed its substrate preferences for shorter alkanes (C4-C8) when compared with the native P450~BM3~, which exhibited a substrate preference for Cn \> 8 alkanes \[[@CR19]\]. It could be expected that P450~BM3J~ will have a higher priority for ω3 hydroxylation when using a longer-chain alcohol substrate. So we generated another engineered *E. coli* BM3J that overexpressed P450~BM3J~. The same as BM3, BM3J had no activity on propanol and butanol, and exhibited a low activity on pentanol, with 1,4-pentanediol as the only product (Fig. [2](#Fig2){ref-type="fig"}). But when using heptanol and decanol as substrates, BM3J produced more 1,4-heptanediol and 1,7-decanediol than BM3, with 1,4-heptanediol and 1,7-decanediol accounting for 50.1 and 64.5 % of total heptanediols and decanediols, respectively (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).

To examine if the increased ω-3 hydroxylation is mainly attributed to a specific amino acid substitution, we made 10 single mutants that correspond to the 10 amino acid substitutions of P450~BM3J~, namely, V78A, T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V and L353V. The ratio of 1,7-decanediol to total decanediols increased from 34.0 % in BM3 to \~50 % in R255S (Fig. [3](#Fig3){ref-type="fig"}), suggesting the increased ratio of 1,7-decanediol to total decanediols in BM3J is mainly attributed to the substitution of Arg^255^ to Ser^255^, which allows the ω terminal carbon of the decanol substrate to move a little closer to the Ser^255^, and in the meanwhile to move a little farther away from the heme. This movement makes the ω-1 carbon deviate from its best position for hydroxylation, and thus decreases the efficiency of ω-1 hydroxylation. The other 9 amino acid substitutions may have a combined effect on the constriction of the substrate-binding channel and the change of the substrate orientation (Fig. [4b](#Fig4){ref-type="fig"}).Fig. 4Three-dimensional structures of P450~BM3~ and its variants. P450~BM3~ heme domain with palmitoleic acid bound was obtained from 1FAG (**a**). SWISS-MODEL derived homology models of P450~BM3~ variant structures, using 1FAG as the template (**b**, **c**, **d**). The amino acid residues involved in laboratory evolution are depicted in stick symbols. B, P450~BM3J~; C, P450~J2~; D, P450~J2-F87A~

The effect of heme end residues on the regioselectivity of P450~BM3J~ {#Sec5}
---------------------------------------------------------------------

To further improve the regioselectivity of P450~BM3J~, we need to further constrict the substrate-binding channel. The Val^78^ in P450~BM3~ is located near the ω terminus of fatty acid substrates, so it may be vital in controlling the substrate orientation. Fatty alcohol substrates should have a quite similar substrate orientation in the active site to the fatty acid substrates, which can be reflected by the regioselectivity for heptanol and decanol hydroxylation. The substitution of Val^78^ in P450~BM3~ to Ala^78^ in P450~V78A~ nearly does not change the regioselectivity for decanol, as alanine has a similar property to valine. But when the Ala^78^ in P450~BM3J~ was substituted to Phe^78^, yielding a variant J2, the ratio of 1, 7-decanediol (ω-3 hydroxylation) to total decanediols further increased to 76.3 % from 64.5 % in BM3J (Fig. [5](#Fig5){ref-type="fig"}). The phenyl group of Phe^78^ creates a narrower space between Phe^78^ and the heme. This conformational change forced the carbon chain bend, made the ω, ω-1 and ω-2 terminal carbons move farther away from the heme, and finally resulted in the decrease of undesired ω-1 and ω-2 hydroxylation (Fig. [4c](#Fig4){ref-type="fig"}). Therefore, the residues located around the heme end of the substrate-binding channel indeed play more important roles in determining the regioselectivity of the alcohol hydroxylases for medium-chain alcohol substrates.Fig. 5Regioselectivities of native P450~BM3~ and its variants for decanol. Decanol was used as substrate, and product decanediols were analyzed by GC-MS. 1,7-, 1,8- and 1,9-decanediols represent ω-3, ω-2 and ω-1 hydroxylation, respectively. BM3 expresses the native P450~BM3~, while BM3J, J2, J2-R47L and J2-F87A express different P450~BM3~ variants

To test this hypothesis, two residues, Arg^47^ and Phe^87^, were chosen for further modification. Arg^47^ is located at the mouth of substrate binding site and its guanidinium group is thought to provide an important ion-pair interaction with the carboxylate group of the fatty acid substrates \[[@CR20]\], while Phe^87^ is located above the heme and is known to be an important factor in determining the regioselectivity of substrate hydroxylation \[[@CR21]\]. The substitution of Arg^47^ to Leu^47^ was found to increase the hydroxylase activity towards pentane and propylbenzene \[[@CR13]\]. The R47L mutation was then incorporated into the variant J2, generating a new variant J2-R47L. As expected, the regiospecificity profile of J2-R47L was nearly the same as that of J2 (Fig. [5](#Fig5){ref-type="fig"}), demonstrating the substitution of Arg^47^ to Leu^47^ did not change the substrate orientation and had little connection with the regioselectivity for alcohol substrates. But when the Phe^87^ was substituted to Ala^87^ (J2-F87A), the ratio of 1,7-decandediol to total decanediols further increased to 86.8 % (Fig. [5](#Fig5){ref-type="fig"}). The substitution of Phe^87^ to Ala^87^ released the space for the α-terminus of decanol to move towards the heme, and in the meanwhile made the benzene ring of Phe^78^ rotate away from the ω terminus of decanol (Fig. [4d](#Fig4){ref-type="fig"}). This incident allowed the ω, ω-1 and ω-2 terminal carbons of decanol to further move away from the heme, leading to the increased distribution of 1,7-decandediol. The heme end residues are responsible for contraction or expansion of the hydrophobic pocket, so they can affect the alcohol orientation in the substrate-binding channel and finally control the regioselectivity of the alcohol hydroxylation.

Conclusions {#Sec6}
===========

The engineering strategy described above inaugurates a new realm for the high-specificity production of 1,7-decanediol, which is a promising monomer for the development of advanced materials. The desired 1,7-decanediol was finally produced, being the first successful report on the biosynthesis of diols with one hydroxyl group at the subterminus. The regiospecificity of alcohol hydroxylation was greatly improved by laboratory evolution. Conservative structural models of the P450~BM3~ variants demonstrate that the heme end residues in the substrate-binding channel play a key role in determining the regioselectivity for medium-chain alcohols. This study not only provides a good strategy for the biosynthesis of 1,7-decanediol, but also gives a promising approach for the production of other useful diols. More and more advanced materials can be expected once these new diol monomers are available.

Methods {#Sec7}
=======

Plasmid construction {#Sec8}
--------------------

The *P450*~*BM3*~ gene was amplified from genomic DNA of *Bacillus megaterium* ATCC 14581 (NZ_CP009920) with the primer set BM3-NcoF and BM3-BamHR. The PCR product digested with NcoI and BamHI was cloned into pCOLADuet-1 (Novagen, Darmstadt, Germany) cut with the same restriction enzymes, creating pLQ12. P450~BM3J~ was generated by introducing 10 amino acid mutations (V78A, T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V) on P450~BM3~ \[[@CR19]\]. The codon-optimized 1129 bp necleic acids coding for the N-terminal P450~BM3J~ were chemically synthesized, amplified with the primer set BM3J-NcoF and BM3J-EcoR, and integrated into the pCOLADuet-1, creating the plasmid pZZ1-up. The other part of the *P450*~*BM3J*~ gene, which is the same as that of *P450*~*BM3*~ gene, was amplified from genomic DNA of *B. megaterium* (ATCC 14581) with the primer set BM3J-EcoF and BM3J-NotR. The PCR product digested with EcoRI and NotI was cloned into pZZ1-up cut with the same restriction enzymes, creating pZZ1. The whole *P450*~*BM3J*~ gene sequence is shown in \[Additional file [1](#MOESM1){ref-type="media"}: Figure S1\].

Structure modeling and site-directed mutagenesis {#Sec9}
------------------------------------------------

The models of the P450 variant structures were built on a public server Swiss-Model, using 1FAG as the template \[[@CR22]--[@CR24]\]. A method based on the amplification of the entire plasmid using primers that include the desired changes was employed for the site-directed mutagenesis \[[@CR25]\]. All the plasmids and strains used in this work are listed in Table [1](#Tab1){ref-type="table"}, and the oligonucleotide primers are given in Table [2](#Tab2){ref-type="table"}.Table 1Bacterial strains and plasmids used in this studyPlasmid or strainRelevant genotype or descriptionReferencePlasmids pCOLADuet-1ColA origin; Kan^R^; P~T7~Novagen pLQ12ColA origin; Kan^R^; P~T7~:: *P450* ~*BM3*~This study pZZ1ColA origin; Kan^R^; P~T7~:: *P450* ~*BM3J*~This study pV78AColA origin; Kan^R^; P~T7~:: *P450* ~*BM3V78A*~This study pT175IColA origin; Kan^R^; P~T7~:: *P450* ~*BM3T175I*~This study pA184VColA origin; Kan^R^; P~T7~:: *P450* ~*BM3A184V*~This study pF205CColA origin; Kan^R^; P~T7~:: *P450* ~*BM3F205C*~This study pS226RColA origin; Kan^R^; P~T7~:: *P450* ~*BM3S226R*~This study pH236QColA origin; Kan^R^; P~T7~:: *P450* ~*BM3H236Q*~This study pE252GColA origin; Kan^R^; P~T7~:: *P450* ~*BM3E252G*~This study pR255SColA origin; Kan^R^; P~T7~:: *P450* ~*BM3R255S*~This study pA290VColA origin; Kan^R^; P~T7~:: *P450* ~*BM3A290V*~This study pL353VColA origin; Kan^R^; P~T7~:: *P450* ~*BM3L353V*~This study pJ2ColA origin; Kan^R^; P~T7~:: *P450* ~*BM3JA78F*~This study pJ2-R47LColA origin; Kan^R^; P~T7~:: *P450* ~*BM3JA78FR47L*~This study pJ2-F87AColA origin; Kan^R^; P~T7~:: *P450* ~*BM3JA78F87A*~This studyStrains BL21(DE3)*E. coli B dcm ompT hsdS*(r~B~ ^−^m~B~ ^−^) *gal*Invitrogen LQ12BL21(DE3) harboring pLQ12This study ZZ1BL21(DE3) harboring pZZ1This study V78ABL21(DE3) harboring pV78AThis study T175IBL21(DE3) harboring pT175IThis study A184VBL21(DE3) harboring pA184VThis study F205CBL21(DE3) harboring pF205CThis study S226RBL21(DE3) harboring pS226RThis study H236QBL21(DE3) harboring pH236QThis study E252GBL21(DE3) harboring pE252GThis study R255SBL21(DE3) harboring pR255SThis study A290VBL21(DE3) harboring pA290VThis study L353VBL21(DE3) harboring pL353VThis study J2BL21(DE3) harboring pJ2This study J2-R47LBL21(DE3) harboring pJ2-R47LThis study J2-F87ABL21(DE3) harboring pJ2-F87AThis studyTable 2Primers used in this studyNameSequence (5′ → 3′)BM3-NcoFCTTG[CCATGG]{.ul}GCATGACAATTAAAGAAATGCCTCAGBM3-BamRCG[GGATCC]{.ul}TTACCCAGCCCACACGTCTTTTGBM3J-NcoFCATG[CCATGG]{.ul}GCATGACAATTAAAGAAATGCCTCAGBM3J-EcoRGACG[GAATTC]{.ul}TTCCACATCGBM3J-EcoFGAA[GAATTC]{.ul}CGTCCAGAGCGTTTTGBM3J-NotRATAAGAAT[GCGGCCGC]{.ul}TTACCCAGCCCACACGTCTTTTGBM3-V78A-FGCTTAAATTTGCACGTGATTTTGCAGGAGACGGBM3-V78A-RCAAAATCACGTGCAAATTTAAGCGCTTGACTTAAGBM3-T175I-FCCATTTATTATCAGTATGGTCCGTGCACTGGATGBM3-T175I-RGACCATACTGATAATAAATGGATGAGGCTGATCBM3-A184V-FGGATGAAGTAATGAACAAGCTGCAGCGAGCBM3-A184V-RCTTGTTCATTACTTCATCCAGTGCACGGACCBM3-F205C-FCAAGCGCCAGTGTCAAGAAGATATCAAGGTGBM3-F205C-RCTTCTTGACACTGGCGCTTGTTTTCATCATAAGBM3-S226R-FCGCAAAGCACGCGGTGAACAAAGCGATGBM3-S226R-RGTTCACCGCGTGCTTTGCGATCTGCBM3-H236Q-FCGCAGATGCTAAACGGAAAAGATCCAGBM3-H236Q-RCCGTTTAGCATCTGCGTTAATAAATCATCBM3-E252G-FGATGACGGGAACATTCGCTATCAAATTATTACBM3-E252G-RGCGAATGTTCCCGTCATCAAGCGGCTCACCCGBM3-R255S-FGACGAGAACATTAGCTATCAAATTATTACATTCBM3-R255S-RGATAGCTAATGTTCTCGTCATCAAGCGGCTCACBM3-A290V-FGTATTACAAAAAGTAGCAGAAGAAGCAGCBM3-A290V-RCTTCTGCTACTTTTTGTAATACATGTGGBM3-L353V-FGCGACGAAGTAATGGTTCTGATTCCTCAGCBM3-L353V-RGAACCATTACTTCGTCGCCTTTTTCTAAAGGBM3J-A78F-FGCGCTGAAATTTTTCCGTGATTTTGCAGGTGACGGBM3J-A78F-RCAAAATCACGGAAAAATTTCAGCGCTTGACTTAAGJ2-R47L-FGCGCCTGGTCTGGTAACGCGCTACTTATCAAGJ2-R47L-RCGCGTTACCAGACCAGGCGCCTCGAATTTAAAGJ2-F87A-FGACGGGTTGGCTACAAGCTGGACGCATGJ2-F87A-RGCTTGTAGCCAACCCGTCACCTGCAAAATCUnderlines indicate restriction enzyme sites

Bacterial strains, media and growth conditions {#Sec10}
----------------------------------------------

The bacterial strains used in this study are listed in Table S1. *E. coli* BL21(DE3) (Invitrogen, Carlsbad, CA) was used as the host to overproduce proteins. During strain construction, cultures were grown aerobically at 37 °C in LB medium (10 g/L tryptone, 10 g/L NaCl, and 5 g/L yeast extract). Kanamycin (50 mg/L) was added if necessary. For initial protein over-production in shake flasks, cultures were firstly grown in LB medium containing 50 mg/L kanamycin, then induced with 0.5 mM isopropyl β-D-thiogalactoside (IPTG), next incubated at 30 °C for 10 h, and finally harvested by centrifugation. The cell catalysts obtained from 50 ml cultures were transferred into 25 ml M9 medium (37.8 g/L Na~2~HPO~4~ · 12H~2~O, 7.5 g/L KH~2~PO~4~, 1 g/L NH~4~Cl, 0.5 g/L NaCl, 4 mM MgSO4) supplemented with 50 mg/L kanamycin, 0.25 mM IPTG and 5 mM alcohols, and incubated at 30 °C for 48 h.

Analysis of diols by GC-MS {#Sec11}
--------------------------

Different diols produced by the engineered strains were identified by gas chromatography--mass spectrometry (GC--MS). These diols were isolated by ethyl acetate extraction. After concentrated by a rotary evaporator and redissolved with ethanol, 1 μl sample was injected for GC-MS analysis. The system consisted of model 7890A network GC system (Agilent Technologies) and a model 5975C network mass selective detector (Agilent Technologies, Santa Clara, CA). A HP-INNOWAX capillary column (30 m × 0.25 mm; 0.25 μm film thickness; Agilent Technologies) was used, with helium as the carrier gas. The following oven temperature program was carried out: 50 °C for 2 min, increase of 10 °C/min to 240 °C, 240 °C for 5 min. The injector was maintained at 250 °C.

Additional file {#Sec12}
===============

Additional file 1: Figure S1.Nucleotide sequence of P450~BM3J~. (DOCX 30 kb)

*E. coli*

:   *Escherichia coli*
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